recentpopularlog in


« earlier   
(2179) Volksdroge Alkohol – warum dürfen wir uns zu Tode trinken? | DokThema | Doku - YouTube
die Kosten des Alkohols:
health economics 10x mehr kosten als steuern und arbeitsplaetze
alkohol steuer + werbeverbot (1mrd eur pro jahr deutschland) + verfuegbarkeitseinschaenkungen
Alcohol  public  health  prevention  Cancer  self-medication  abuse  NAFLD  obesity  economics  nudge  lobby  vested  interest 
52 minutes ago by asterisk2a
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies | PracticeUpdate
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
JAMA network open.
 1 Expert Comment
Save Recommend Share Get Topic Alerts

In this observational study of 99 cancer drugs approved by the FDA from 1989 to 2017, the median income return by the end of 2017 was $14.50 (range, $3.30–$55.10) for every $1 of research and development spending. Many drugs, particularly biologics, continued to generate high-sales incomes for the originator companies after expiry of patents and exclusive marketing rights.
Cancer drugs, through high prices, have generated incomes for the companies far in excess of research and development costs; lowering the prices of cancer drugs and facilitating greater competition are essential for improving patient access, financial sustainability of the healthcare system, and future innovation.
cancer  HealthCare  Economics 
yesterday by cnk
Don’t abandon sunscreen just yet • Slate
Shannon Palus, following up on that surprising story (linked earlier this week) which suggested that we shouldn't use sunscreen because it could lead to vitamin D deficiency:
<p>even sunscreen-adherents end up spending a non-negligible amount of their time outdoors uncovered, allowing Vitamin D in. And the amount of sun exposure you need to get Vitamin D is actually pretty minimal: experts advocating sun exposure as the best way to absorb the vitamin say that you should spend on the order of 10 to 30 minutes three times a week with your arms and legs exposed during midday in the summer for ideal exposure (it’s impossible to give an exact amount, as that will vary by location and skin tone, and yes, as Jacobson notes, it seems possible this recommendation is geared toward light-skinned folks). But even considering that a low estimate, it’s an extremely easy level of exposure if you’re spending a day outside—even if you wear sunscreen.

Jacobson takes pains throughout his piece to acknowledge that his thesis is supported by a new, small line of research that is regarded with skepticism within the dermatology community, which is all the more reason not to take the piece as advice on how to live your daily life, at least not yet. But it’s not clear that some of the main pieces of evidence for this rogue take are even correct. For example, he strangely evokes the health of “our ancestors” who “lived outdoors in tropical regions and ran around half naked” without noting the improvements in lifespan since, despite that being an incredibly relevant factor to cancer incidence.

Jacobson’s article does contain an important truth: Sunscreen isn’t a one-size-fits-all prescription.
Some of the more rigorous research seems like weak support, too. </p>

I'm glad this article appeared, because an Overspill reader with a lot of expertise in this subject (who doesn't want to be identified, but pointed me to this) had suggested that the original might be overstating the case. "Having been a melanoma researcher, I wear sunscreen every day," in their words. So, your decision. But the scientists aren't moved at present.
cancer  skin  vitamind  sunscreen 
3 days ago by charlesarthur
Converting Cancer Cells to Fat Cells to Stop Cancer’s Spread
The team were able to transform EMT-derived breast cancer cells into fat cells in a mouse model of the disease – preventing the formation of metastases.
science  medicine  cancer 
4 days ago by emkay
Are Andrew Lansley's NHS reforms being binned? - BBC News
But Nigel Edwards, the influential chief executive of the Nuffield Trust think tank, believes a "significant unpicking" of Mr Lansley's reforms are on the cards and in time they will be judged as "one of the most major public policy failures" of all time.

If that is the case, it begs the question: why did the government go to all the trouble of pushing ahead with them in the first place?
NHS  Privatisation  long-term  plan  sickcare  ageing  population  Conservative  Party  premature  chronic  sick  prevention  public  health  CVD  dementia  Cancer  Austerity  social  care  Council  elderly  CCG  GP 
5 days ago by asterisk2a
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease | NEJM
Original Article from The New England Journal of Medicine — Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
vitamin  D  cancer 
5 days ago by alexmel
Predicting Tumor Patterns Using Ubiquitin Pathway Genes | Cancer Network
Cancer Network: What functions does protein ubiquitination play in healthy cells?

Dr. Liang: Protein ubiquitination functions in a variety of biological processes including protein degradation via the proteasome, protein subcellular localization alteration, protein activation, and protein interactions.

Cancer Network: What makes the ubiquitin pathway a promising target for cancer research?

Dr. Liang: There are two main reasons. First, there has been extensive evidence relating malfunction of the ubiquitin pathway with tumor initiation and progression. Second, unlike standard targeted therapy which targets a protein’s biological activity, targeting the ubiquitin pathway regulates the protein levels and can be used for undruggable targets such as MYC and b-catenin.

Cancer Network: How did your team go about identifying candidate tumor-driving ubiquitin-related genes?

Dr. Liang: Using the genomic and proteomic data from The Cancer Genome Atlas, we performed comprehensive molecular characterization of a manually curated list of 928 ubiquitin-related genes and 95 deubiquitinase genes across 9,125 patients from 33 cancer types. We used a variety of bioinformatics algorithms to identify candidate tumor-driving ubiquitin-related genes, including [The Broad Institute’s] MutSigCV for mutation drivers (those genes accumulating more mutations than expected) and GISTIC2 for copy number alteration drivers (those genes showing unusually high frequency of amplifications or deletions in tumors).

Cancer Network: What did you find?

Dr. Liang: There are three key findings in our study. First, candidate ubiquitin pathway drivers which had significant somatic mutation and copy number alterations were systematically cataloged. Second, genes in the ubiquitin pathway tend to be overexpressed in a range of cancer types compared to their matched normal tissues. Finally, our multi-platform integrative analysis of ubiquitin pathway genes revealed a group of patients who consistently correlated with worse prognosis across cancer types. And these patients showed differential ubiquitin pathway expression underlying the perturbation of many fundamental signaling pathways, notably cell cycle and DNA damage repair.

Cancer Network: How might these findings inform the development of new cancer treatments?

Dr. Liang: Current progress on developing drugs that target ubiquitin system has been limited, partly due to the lack of systemic characterization of driver mutations, copy number alteration patterns, and dysregulated expression profiles in the ubiquitin pathway across cancer types. This study hopefully lays [the groundwork] for exploring ubiquitin pathway genes that are cancer molecular drivers and of clinical relevance as drug candidates and prognostic markers.
genomics  cancer 
5 days ago by cnk

Copy this bookmark:

to read